Repligen Corp. said Monday that a mid-stage clinical trial showed one of its drug candidates was no more effective than a placebo in treating bipolar depression.
According to Yahoo! finance the company has over $50M in cash vs $0 debt; do quick look at studies & deside if termination of just one of the Phase II trials cost the Repligen 30% of the market cap losses.